Anaplastic Lymphoma Kinase Inhibitor in Treatment of Inflammatory Myofibroblastic Tumor of the Tongue in Infancy

J Pediatr Hematol Oncol. 2021 May 1;43(4):e521-e524. doi: 10.1097/MPH.0000000000001907.

Abstract

Inflammatory myofibroblastic tumors (IMTs) are rare in neonates. IMTs of the tongue are also very rare in infancy, with only 1 case reported in this age group. The mainstay of therapy has traditionally been surgery, which can be devastating to surrounding structures and negatively impact prognosis. Approximately 50% of IMTs harbor a translocation involving the anaplastic lymphoma kinase gene. We describe a case of IMT of the tongue in a neonate treated with debulking and an anaplastic lymphoma kinase inhibitor. The patient achieved complete response and remains disease-free 1.5 year following completion of therapy.

Publication types

  • Case Reports

MeSH terms

  • Anaplastic Lymphoma Kinase / antagonists & inhibitors*
  • Female
  • Humans
  • Infant, Newborn
  • Neoplasms, Muscle Tissue / drug therapy*
  • Neoplasms, Muscle Tissue / pathology
  • Protein Kinase Inhibitors / therapeutic use*
  • Tongue Neoplasms / drug therapy*
  • Tongue Neoplasms / pathology
  • Treatment Outcome

Substances

  • Protein Kinase Inhibitors
  • ALK protein, human
  • Anaplastic Lymphoma Kinase